NovoCure (NVCR) Net Income towards Common Stockholders (2014 - 2026)

NovoCure (NVCR) has reported Net Income towards Common Stockholders for 13 consecutive years, with -$15.7 million the latest figure, recorded in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 60.99% year-over-year to -$15.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$148.6 million (up 13.09% YoY) and the FY2025 annual result came in at -$136.2 million, up 19.21% from the prior year.
• Net Income towards Common Stockholders advanced to -$15.7 million in Q2 2026 per NVCR's latest filing, from -$71.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for NVCR reached as high as -$4.6 million in Q1 2022 and fell as low as -$71.1 million in Q1 2026.
• A 5-year average of -$38.4 million and a median of -$37.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 1041.83% — and 2025, when it jumped 62.84%.
• Year by year, Net Income towards Common Stockholders stood at -$37.3 million in 2022, then slipped by 26.21% to -$47.1 million in 2023, then sank by 40.02% to -$65.9 million in 2024, then soared by 62.84% to -$24.5 million in 2025, then surged by 36.09% to -$15.7 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$15.7 million, -$71.1 million, and -$24.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.